Page last updated: 2024-12-08

o-desmethylindomethacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(4-chlorobenzoyl)-5-hydroxy-2-methyl-3-indoleacetic acid: has insulin sensitizing and glucose lowering activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159665
CHEMBL ID800
SCHEMBL ID2996680
MeSH IDM0106719

Synonyms (30)

Synonym
demethylindomethacin
1-(4-chlorobenzoyl)-5-hydroxy-2-methyl-3-indoleacetic acid
5-hydroxyindomethacin
desmethyl-indomethacin
o-desmethylindomethacin
2504-32-7
1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-hydroxy-2-methyl-
CHEMBL800
FT-0666136
desmethyl indomethacin
[1-(4-chloro-benzoyl)-5-hydroxy-2-methyl-1h-indol-3-yl]-acetic acid
[1-(4-chloro-benzoyl)-5-hydroxy-2-methyl-1h-indol-3-yl]-acetic acid( indomethacin)
bdbm50029074
2-{1-[(4-chlorophenyl)carbonyl]-5-hydroxy-2-methylindol-3-yl}acetic acid
2-[1-(4-chlorobenzoyl)-5-hydroxy-2-methylindol-3-yl]acetic acid
unii-k89vs3uad8
1-(p-chlorobenzoyl)-5-hydroxy-2-methylindole-3-acetic acid
k89vs3uad8 ,
indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-hydroxy-2-methyl-
o-desmethyl indomethacin
desmethylindomethacin
1-(4-chlorobenzoyl)-5-hydroxy-2-methyl-1h-indole-3-acetic acid
SCHEMBL2996680
DTXSID60179746
o-desmethylindomethacin, analytical standard
AKOS030254556
J-015790
ortho-desmethylindomethacin
PD156576
2-(1-(4-chlorobenzoyl)-5-hydroxy-2-methyl-1h-indol-3-yl)acetic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" A pharmacokinetic profile of indomethacin is shown, and some preliminary pharmacokinetic parameters of indomethacin obtained from one human volunteer are given."( Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid.
van den Biggelaar-Martea, M; Verwey-van Wissen, CP; Vree, TB, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Analysis of the NE-cAMP dose-response curve indicates that the stress reduces the maximum cAMP response to NE but does not increase the EC50 value of NE."( Reduction of the cyclic adenosine 3',5'-monophosphate response to catecholamines in rat brain slices after repeated restraint stress.
Platt, JE; Slucky, AV; Stone, EA; Trullas, R, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Bos taurus (cattle)IC50 (µMol)3.20000.00702.589210.0000AID34329
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
retinol metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID304235Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 3 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304236Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 1 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304232Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 100 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304224Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304223Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304245Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 30 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID34329Inhibition of Aldose reductase (AR)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis.
AID304242Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 1 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304243Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 3 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304225Selectivity for human COX2 over human COX12007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304244Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 10 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID304234Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 10 uM relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
AID1570218Antidiabetic activity in db/db mouse assessed as reduction in serum glucose level at 10 to 30 mg/kg, po after 1 week relative to control2019European journal of medicinal chemistry, 10-15, Volume: 180An insight into the medicinal perspective of synthetic analogs of indole: A review.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (18.52)18.7374
1990's10 (37.04)18.2507
2000's8 (29.63)29.6817
2010's4 (14.81)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.18 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]